Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jan 1;106(1):291-294.
doi: 10.3324/haematol.2019.241513.

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Massimo Gentile  1 , Giorgina Specchia  2 , Daniele Derudas  3 , Monica Galli  4 , Cirino Botta  1 , Stefano Rocco  5 , Concetta Conticello  6 , Catello Califano  7 , Nicola Giuliani  8 , Silvia Mangiacavalli  9 , Enrico Attingenti  10 , Alessandra Lombardo  11 , Marino Brunori  12 , Elena Rossi  13 , Elisabetta Antonioli  14 , Roberto Ria  15 , Renato Zambello  16 , Nicola Di Renzo  17 , Giuseppe Mele  18 , Gianpaolo Marcacci  19 , Pellegrino Musto  20 , Silvana Capalbo  21 , Nicola Cascavilla  22 , Claudio Cerchione  23 , Angelo Belotti  24 , Clelia Criscuolo  25 , Giuseppina Uccello  26 , Paola Curci  2 , Ernesto Vigna  1 , Vincenzo Fraticelli  1 , Donatella Vincelli  27 , Angela Bonalumi  28 , Agostina Siniscalchi  29 , Raffaella Stocchi  30 , Massimo Martino  31 , Stelvio Ballanti  32 , Dominella Gangemi  33 , Alfredo Gagliardi  34 , Barbara Gamberi  35 , Alessandra Pompa  36 , Anna Grazia Recchia  37 , Giovanni Tripepi  38 , Annalisa Pitino  39 , Ferdinando Frigeri  10 , Ugo Consoli  26 , Sara Bringhen  40 , Elena Zamagni  41 , Francesca Patriarca  30 , Valerio De Stefano  42 , Francesco Di Raimondo  43 , Salvatore Palmieri  5 , Maria Teresa Petrucci  44 , Massimo Offidani  45 , Mario Boccadoro  40 , Michele Cavo  41 , Fortunato Morabito  46
Affiliations
Multicenter Study

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Massimo Gentile et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival (PFS) of the retrospective cohort of relapse/refractory (RR) multiple myeloma patients treated with lenalidomide plus dexamethasone (Rd) plus elotuzumab (EloRd). Kaplan-Meier curve of PFS of the entire cohort (A). Forest plot of Cox univariate analysis for PFS according to clinical laboratory variables (B). b2M: beta-2-microglobulin; ASCT: autologous stem cell transplant; CrCl: creatinine clearance; CRAB: hypercalcemia, renal failure, anemia, and bone disease; N: number.
See this image and copyright information in PMC

References

    1. Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. 2017;31(5):1039-1047. - PubMed
    1. Durer C, Durer S, Lee S, et al. Treatment of relapsed multiple myeloma: evidence-based recommendations. Blood Rev. 2020;39:100616. - PubMed
    1. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841-1849. - PMC - PubMed
    1. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775-2784. - PMC - PubMed
    1. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552-559. - PMC - PubMed

MeSH terms